Investors & Media
News
Sage Therapeutics Announces Proposed Public Offering of Common Stock
The shares are being offered by Sage pursuant to an automatically
effective shelf registration statement on Form S-3 that was previously
filed with the
When available, copies of the preliminary prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by contacting one of the following:
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About
Forward-Looking Statements
Various statements in this
release concerning Sage's future expectations, plans and prospects,
including without limitation, Sage's expectations regarding the timing
and completion of its proposed public offering of its common stock, and
Sage's plans with respect to its product candidates and other
activities, constitute forward-looking statements for the purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are neither
promises nor guarantees of future performance, and are subject to a
variety of risks and uncertainties, many of which are beyond Sage's
control, which could cause actual results to differ materially from
those indicated by these forward-looking statements, including, without
limitation: the uncertainties related to market conditions and Sage's
ability to complete the public offering on accepted terms or at all; the
risk that Sage may not be able to satisfy the customary closing
conditions related to the proposed offering; the potential that our
completed, ongoing and future clinical and non-clinical data may not be
sufficient to file for or gain regulatory approval to launch and
commercialize our product candidates; the potential that future
pre-clinical and clinical results may not support further development of
Sage's product candidates or that Sage may not be able to successfully
demonstrate the efficacy and safety of its product candidates at each
stage of development in a manner sufficient to obtain approval; the risk
that actions or decisions of regulatory agencies may affect the
initiation, timing and progress of clinical trials; the potential for
unexpected adverse events in the conduct of one of Sage's clinical
trials to impact its ability to continue the clinical trial or further
development of a product candidate; the risk that Sage may encounter
other unexpected hurdles or issues in the development and manufacture of
its product candidates that may impact its timing or progress, as well
as those risks more fully discussed in the section entitled "Risk
Factors" in Sage's most recent quarterly report on Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in Sage's subsequent filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20180207006213/en/
Source:
Sage Therapeutics
Investor Contact:
Paul Cox,
617-299-8377
paul.cox@sagerx.com
or
Media
Contact:
Maureen L. Suda, 585-355-1134
maureen.suda@sagerx.com